Ring OUT

The dose which the patient gets through the mouthpiece of the device is 180 mcg.

Beclometasone (Ring OUT) contains 200 doses of finely powdered beclomethasone dipropionate mixed in a small quantity of lactose. The amount of drug received by the patient (180 mcg/dose) corresponds to that from 2 puffs of the freon-based beclomethasone inhalation aerosol with a metered dose of 100 mcg/dose. The dose to be inhaled is released from the container by pressing the device between the thumb and the forefinger. This is followed by inhalation through the device. As a result, beclomethasone dipropionate particles are transferred to their target, the lungs. Use of the Beclometasone (Ring OUT) does not require coordination of actuation of the dose and inhalation.

Clotrimazole (Ring OUT) is used as a topical ointment or cream in the treatment of Tinea infections. Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton). Commonly these infections are named for the body part affected, including tinea corporis (general skin), tinea cruris (groin), and tinea pedis (feet). Clotrimazole (Ring OUT) is a halogenated phenolic ether administered topically for dermotaphytic infections. The mechanism of action is unknown, but also presumed to interfere with yeast membrane structure and function.

A component of Neomycin (Ring OUT) that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). Neomycin (Ring OUT) is a bactericidal aminoglycoside antibiotic that binds to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and acceptor tRNA sites and results in the production of non-functional or toxic peptides.

Maintenance treatment of asthma as prophylactic therapy in adults and children (≥5 years). For asthma patients who require systemic corticosteroid administration where adding Beclometasone (Ring OUT) dipropionate may reduce or eliminate the need for the systemic corticosteroids.

Beclometasone (Ring OUT) dipropionate is not indicated for the relief of acute bronchospasm.

Clotrimazole (Ring OUT)® Troches are indicated for the local treatment of oropharyngeal candidiasis. The diagnosis should be confirmed by a KOH smear and/or culture prior to treatment.

Clotrimazole (Ring OUT)® Troches are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation. There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Neomycin (Ring OUT) tablets and other antibacterial drugs, Neomycin (Ring OUT) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Suppression of Intestinal Bacteria

Neomycin (Ring OUT) tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, e.g., preoperative preparation of the bowel. It is given concomitantly with erythromycin enteric-coated base.

Hepatic Coma (Portal-Systemic Encephalopathy)

Neomycin (Ring OUT) has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia-forming bacteria in the intestinal tract. The subsequent reduction in blood ammonia has resulted in neurologic improvement.

Beclomethasone is a steroid. It prevents the release of substances in the body that cause inflammation.

Beclomethasone nasal is used to treat nasal symptoms such as congestion, sneezing, and runny nose caused by seasonal or year-round allergies. The Beclometasone (Ring OUT) brand of this medication is also used to keep nasal polyps from coming back after surgery to remove them.

Beclomethasone may also be used for purposes not listed in this medication guide.

Clotrimazole (Ring OUT) lozenges are dissolved slowly in the mouth to prevent and treat thrush. Thrush, also called candidiasis or white mouth, is a fungus infection of the mouth and throat. Clotrimazole (Ring OUT) may also be used for other problems as determined by your doctor.

Clotrimazole (Ring OUT) is available only with your doctor's prescription.

Neomycin (Ring OUT) is an antibiotic that fights bacteria in the body.

Neomycin (Ring OUT) is used to reduce the risk of infection during surgery of your intestines. Neomycin (Ring OUT) is also used to reduce the symptoms of hepatic coma.

Neomycin (Ring OUT) may also be used for purposes not listed in this medication guide.

Management of Chronic Asthma: Adults and Children >12 years: 100-400 mcg twice daily. Maximum: 1000 mcg twice daily.

Children (5-12 years): 100-200 mcg twice daily. Maximum: 200-400 mcg twice daily.

Prophylaxis of Asthma: Adults and Children >12 years: 50-200 mcg twice daily. Increase if necessary to maximum 400 mcg twice daily.

Children (5-12 years): The usual starting dose is 100 mcg twice daily. Depending on the severity of asthma, the daily dose may be increased up to 400 mcg administered in 2-4 divided doses.

When patient's symptoms remain under satisfactory control, the dose should be titrated to the lowest dose at which effective control of asthma is maintained.

Therapy in New Patients: Mild Asthma: 50-100 mcg twice daily.

Moderate Asthma: 100-200 mcg twice daily.

Severe Asthma: 200-400 mcg twice daily.

When switching a patient with well-controlled asthma from another corticosteroid inhaler, initially Beclometasone (Ring OUT) 100 mcg puff should be prescribed for Beclometasone (Ring OUT) dipropionate (CFC) or budesonide 200-250 mcg; fluticasone propionate 100 mcg.

When switching a patient with poorly-controlled asthma from another corticosteroid inhaler, initially Beclometasone (Ring OUT) 100 mcg puff should be prescribed for Beclometasone (Ring OUT) dipropionate (CFC) or budesonide or fluticasone propionate 100 mcg. The dose of Beclometasone (Ring OUT) should be adjusted to response.

Use in the elderly or patients with hepatic or renal impairment: There are no special dosage recommendations for use in the elderly or in patients with hepatic or renal impairment.

Usual Adult Dose for Tinea Corporis

Apply Clotrimazole (Ring OUT) topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 4 weeks, depending on the nature and severity of the infection.

Usual Adult Dose for Tinea Cruris

Apply Clotrimazole (Ring OUT) topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 weeks, depending on the nature and severity of the infection.

Usual Adult Dose for Tinea Pedis

Apply Clotrimazole (Ring OUT) topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 4 to 8 weeks, depending on the nature and severity of the infection.

Usual Adult Dose for Cutaneous Candidiasis

Apply Clotrimazole (Ring OUT) topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 to 4 weeks, depending on the nature and severity of the infection.

Usual Adult Dose for Tinea Versicolor

Apply Clotrimazole (Ring OUT) topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 to 4 weeks, depending on the nature and severity of the infection.

Usual Adult Dose for Vaginal Candidiasis

Regimen 1: 100 mg (one 100 mg vaginal suppository) intravaginally once a day for 7 consecutive days alone or in combination with topical application of 1% Clotrimazole (Ring OUT) to affected area two times daily for 7 consecutive days.

Regimen 2: 200 mg (one 200 mg vaginal suppository) intravaginally once a day for 3 consecutive days alone or in combination with topical application of 1% Clotrimazole (Ring OUT) to affected area two times daily for 7 consecutive days.

Regimen 3: 500 mg (one 500 mg vaginal suppository) intravaginally once.

Regimen 4: One applicatorful of 1% Clotrimazole (Ring OUT) vaginal cream intravaginally once daily (preferably at bedtime) for 7 consecutive days.

Regimen 5: One applicatorful of 2% Clotrimazole (Ring OUT) vaginal cream intravaginally once daily (preferably at bedtime) for 3 consecutive days.

Studies have shown the three and seven day courses of Clotrimazole (Ring OUT) to be equally effective. Patient compliance may be increased with a three day course. Patients who fail to achieve a cure with a single 500 mg dose should be treated with a 3 or 7 day course of Clotrimazole (Ring OUT).

Weekly or monthly Clotrimazole (Ring OUT) vaginal suppositories appear to be effective topical regimens for chronic suppressive therapy in female patients with HIV.

Usual Pediatric Dose for Tinea Corporis

> 3 years: Apply Clotrimazole (Ring OUT) topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 4 weeks, depending on the nature and severity of the infection.

Usual Pediatric Dose for Tinea Cruris

> 3 years: Apply Clotrimazole (Ring OUT) topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 weeks, depending on the nature and severity of the infection.

Usual Pediatric Dose for Tinea Pedis

> 3 years: Apply Clotrimazole (Ring OUT) topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 4 to 8 weeks, depending on the nature and severity of the infection.

Usual Pediatric Dose for Cutaneous Candidiasis

> 3 years: Apply Clotrimazole (Ring OUT) topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 to 4 weeks, depending on the nature and severity of the infection.

Usual Pediatric Dose for Tinea Versicolor

> 3 years: Apply Clotrimazole (Ring OUT) topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 to 4 weeks, depending on the nature and severity of the infection.

Usual Pediatric Dose for Vaginal Candidiasis

> 12 years: Regimen 1: 100 mg (one 100 mg vaginal suppository) intravaginally once a day for 7 consecutive days alone or in combination with topical application of 1% Clotrimazole (Ring OUT) to affected area two times daily for 7 consecutive days.

Regimen 2: 200 mg (one 200 mg vaginal suppository) intravaginally once a day for 3 consecutive days alone or in combination with topical application of 1% Clotrimazole (Ring OUT) to affected area two times daily for 7 consecutive days.

Regimen 3: 500 mg (one 500 mg vaginal suppository) intravaginally once.

Regimen 4: One applicatorful of 1% Clotrimazole (Ring OUT) vaginal cream intravaginally once daily (preferably at bedtime) for 7 consecutive days.

Studies have shown the three and seven day courses of Clotrimazole (Ring OUT) to be equally effective. Patient compliance may be increased with a three day course. Patients who fail to achieve a cure with a single 500 mg dose should be treated with a 3 or 7 day course of Clotrimazole (Ring OUT).

Weekly or monthly Clotrimazole (Ring OUT) vaginal suppositories appear to be effective topical regimens for chronic suppressive therapy in female patients with HIV.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dialysis

Data not available

To minimize the risk of toxicity, use the lowest possible dose and the shortest possible treatment period to control the condition. Treatment for periods longer than two weeks is not recommended.

Hepatic Coma

For use as an adjunct in the management of hepatic coma, the recommended dose is 4-12 grams per day given in the following regimen:

1. Withdraw protein from diet. Avoid use of diuretic agents.

2. Give supportive therapy, including blood products, as indicated.

3. Give Neomycin (Ring OUT) Tablets in doses of 4-12 grams of Neomycin (Ring OUT) per day (eight to 24 tablets) in divided doses. Treatment should be continued over a period of five to six days, during which time protein should be returned incrementally to the diet.

4. If less potentially toxic drugs cannot be used for chronic hepatic insufficiency, Neomycin (Ring OUT) in doses of up to four grams daily (eight tablets per day) may be necessary. The risk for the development of Neomycin (Ring OUT)-induced toxicity progressively increases when treatment must be extended to preserve the life of a patient with hepatic encephalopathy who has failed to fully respond. Frequent periodic monitoring of these patients to ascertain the presence of drug toxicity is mandatory. Also, Neomycin (Ring OUT) serum concentrations should be monitored to avoid potentially toxic levels. The benefits to the patient should be weighed against the risks of nephrotoxicity, permanent ototoxicity and neuromuscular blockade following the accumulation of Neomycin (Ring OUT) in the tissues.

Preoperative Prophylaxis for Elective Colorectal Surgery

Listed below is an example of a recommended bowel preparation regimen. A proposed surgery time of 8:00 am. has been used.

Pre-op Day 3: Minimum residue or clear liquid diet. Bisacodyl, 1 tablet orally at 6:00 p. m.

Pre-op Day 2: Minimum residue or clear liquid diet. Magnesium sulfate, 30 mL, 50% solution (15 g) orally at 10:00 a.m., 2:00 p.m., and 6:00 p.m. Enema at 7:00 p.m. and 8:00 p.m.

Pre-op Day 1: Clear liquid diet. Supplemental (IV) fluids as needed. Magnesium sulfate, 30 mL, 50% solution (15 g) orally at 10:00 a. m., and 2:00 p.m. Neomycin (Ring OUT) (1 g) and erythromycin base (1 g) orally at 1:00 p. m., 2:00 p.m. and 11:00 p.m. No enema.

Day of Operation: Patient evacuates rectum at 6:30 a.m. for scheduled operation at 8:00 a.m.

How supplied

Neomycin (Ring OUT) Tablets, USP, 500 mg (equivalent to 350 mg of Neomycin (Ring OUT) base per tablet) are available as round, off-white, unscored tablets, imprinted "BL" and "18", in bottles of 100 tablets.

Store at controlled room temperature 15°-30° C( 59°-86° F). Dispense in tight containers as defined in the USP/NF.

CAUTION: Federal law prohibits dispensing without prescription.

Hypersensitivity to Beclometasone (Ring OUT) diproprionate or to any of the excipients of Beclometasone (Ring OUT).

See also:
What is the most important information I should know about Clotrimazole (Ring OUT)?

Possible sensitivity to Clotrimazole (Ring OUT).

Rosacea, acne, perioral dermatitis, tuberculosis of the skin and varicose ulcers.

Clotrimazole (Ring OUT) is not indicated for ophthalmic use and should be used with caution around the eyes.

Teratogenicity: Corticosteroids have been shown to be teratogenic in animals following dermal application. As these agents are absorbed percutaneously, teratogenicity following topical application cannot be excluded.

Use in pregnancy: Clotrimazole (Ring OUT) should not be used during pregnancy.

See also:
What is the most important information I should know about Neomycin (Ring OUT)?

You should not take this medicine if you are allergic to Neomycin (Ring OUT) or similar antibiotics such as amikacin (Amikin), gentamicin (Garamycin), kanamycin (Kantrex), paromomycin (Humatin, Paromycin), streptomycin, or tobramycin (Nebcin, Tobi).

You should not take Neomycin (Ring OUT) if you have ulcerative colitis, Crohn's disease, a blockage in your intestines, or other inflammatory bowel disease.

Do not use Neomycin (Ring OUT) if you are pregnant. It could harm the unborn baby.

Before you take Neomycin (Ring OUT), tell your doctor if you have kidney disease, myasthenia gravis, or Parkinson's disease.

Never take Neomycin (Ring OUT) in larger amounts than recommended, or for longer than 2 weeks. High doses or long-term use of Neomycin (Ring OUT) can cause serious kidney problems, or hearing loss that may not be reversible. The longer you take Neomycin (Ring OUT), the more likely you are to develop these serious side effects.

To be sure this medication is not causing harmful effects, your kidney function, and your nerve and muscle function will need to be tested often. You may also need hearing tests. Neomycin (Ring OUT) can have long lasting effects on your body. Do not miss any follow up visits to your doctor for blood or urine tests.

Neomycin (Ring OUT) can harm your kidneys, and this effect is increased when you also use certain other medicines harmful to the kidneys. Before using Neomycin (Ring OUT), tell your doctor about all other medicines you use. Many other drugs (including some over-the-counter medicines) can be harmful to the kidneys.

If you are being treated for hepatic coma, avoid eating foods that are high in protein. Follow your doctor's instructions about any other restrictions on food, beverages, or activity.

Use Clotrimazole (Ring OUT) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• An extra patient leaflet is available with Clotrimazole (Ring OUT). Talk to your pharmacist if you have questions about this information.
• Clotrimazole (Ring OUT) is for vaginal use only. Do not use in the eyes or take by mouth.
• Some forms of this product come with 3 disposable applicators. If this product contains disposable applicators, throw away each applicator after use.
• Some forms of this product come with one applicator to be used for all 3 days of treatment. If this product contains only one applicator, do not throw it away after use. Separate the pieces of the applicator and wash with warm, soapy water immediately after use. Rinse thoroughly. Make sure the applicator is completely dry before the next use.
• If you are using this cream externally, squeeze a small amount onto your fingertip and gently apply to the irritated skin around the vagina.
• Wash your hands immediately after using Clotrimazole (Ring OUT).
• To clear up your infection completely, use Clotrimazole (Ring OUT) for the full course of treatment. Keep using it even if you feel better in a few days.
• If you miss a dose of Clotrimazole (Ring OUT), use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Clotrimazole (Ring OUT).

Use Neomycin (Ring OUT) solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Neomycin (Ring OUT) solution by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
• Take Neomycin (Ring OUT) solution with plenty of water to avoid dehydration.
• Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
• Take Neomycin (Ring OUT) solution on a regular schedule to get the most benefit from it.
• To clear up your infection completely, use Neomycin (Ring OUT) solution for the full course of treatment. Keep using it even if you feel better in a few days.
• If you miss a dose of Neomycin (Ring OUT) solution, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once. If more than one dose is missed, contact your health care provider.

Ask your health care provider any questions you may have about how to use Neomycin (Ring OUT) solution.

Beclometasone (Ring OUT) is used to treat runny nose, swelling and itching of the nose due to allergy (allergic rhinitis), hay fever and ulcerative colitis. Beclometasone (Ring OUT) reduces inflammation, swelling and irritation in nose and helps to relieve itching, sneezing and blocked or runny nose. It is also used in asthma and ulcerative colitis.

This product is a combination of B vitamins used to treat or prevent vitamin deficiency due to poor diet, certain illnesses, alcoholism, or during pregnancy. Vitamins are important building blocks of the body and help keep you in good health. B vitamins include thiamine, riboflavin, niacin/niacinamide, vitamin B6, vitamin B12, folic acid, and pantothenic acid.

Some brands of B vitamins also contain ingredients such as vitamin C, vitamin E, biotin, or zinc. Consult your doctor or pharmacist if you have questions about the ingredients in your brand.

How to use Bco

Take this medication by mouth, usually once daily or as directed. Follow all directions on the product package. If you are uncertain about any of the information, consult your doctor or pharmacist.

If you are taking a brand that contains vitamin C, take this medication by mouth with a full glass of water (8 ounces/240 milliliters) unless your doctor directs you otherwise.

If you are taking chewable tablets, chew the tablet thoroughly before swallowing.

If you are taking extended-release capsules, swallow them whole. Do not crush or chew extended-release capsules or tablets. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split extended-release tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.

If you are taking a liquid product, use a medication-measuring device to carefully measure the dose. Do not use a household spoon. Some liquid products need to be shaken before each dose. Some products that contain vitamin B12 need to be placed under the tongue and held there before swallowing. Follow label directions carefully to get the most benefit.

Take this medication regularly in order to get the most benefit from it. To help you remember, take it at the same time each day.

Oral Neomycin (Ring OUT) is used before the operation of the gut to kill the bacteria which normally live in the gut that may cause a serious infection and in treatment of patients with coma due to liver disease (hepatic coma).

See also:
What other drugs will affect Beclometasone (Ring OUT)?

Due to the very low plasma concentration achieved after inhaled dosing, clinically significant drug interactions are in general unlikely. Care should be taken when co-administering with known strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nelfinavir, ritonavir) as there is a potential for increased systemic exposure to Beclometasone (Ring OUT).

See also:
What other drugs will affect Clotrimazole (Ring OUT)?

Clotrimazole (Ring OUT) should be used cautiously in patients with hyperthyroidism, hypertension and cardiac arrhythmias. All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.

Clotrimazole (Ring OUT) should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.

Combined effects may induce serious cardiac arrhythmias. They may be administered alternately when the preceding effect of other such drug has subsided.

Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia.. When encountered, such arrhythmias may respond to administration of a beta-adrenergic blocking drug. Clotrimazole (Ring OUT) also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.

Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.

Clotrimazole (Ring OUT) may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.

See also:
What other drugs will affect Neomycin (Ring OUT)?

Acarbose: Neomycin (Ring OUT) may enhance the adverse/toxic effect of Acarbose. Neomycin (Ring OUT) may decrease the metabolism of Acarbose. Monitor therapy

Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Arbekacin: May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides. Monitor therapy

Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides. Avoid combination

Bacitracin (Systemic): Neomycin (Ring OUT) may enhance the nephrotoxic effect of Bacitracin (Systemic). Avoid combination

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy

Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. Monitor therapy

Botulinum Toxin-Containing Products: Aminoglycosides may enhance the neuromuscular-blocking effect of Botulinum Toxin-Containing Products. Monitor therapy

Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides. Monitor therapy

CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. Monitor therapy

Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Monitor therapy

Cefazedone: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Cephalothin: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Cephradine: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

CISplatin: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Management: Avoid coadministration of colistimethate and aminoglycosides whenever possible due to the risk of nephrotoxicity and neuromuscular blockade. If coadministration cannot be avoided, monitor renal and neuromuscular function. Consider therapy modification

CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Monitor therapy

Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. Monitor therapy

Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides. Avoid combination

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy

Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity. Monitor therapy

Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides. Avoid combination

Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. Avoid combination

Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. Avoid combination

Neuromuscular-Blocking Agents: Aminoglycosides may enhance the therapeutic effect of Neuromuscular-Blocking Agents. Monitor therapy

Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants. Monitor therapy

Oxatomide: May enhance the ototoxic effect of Aminoglycosides. Monitor therapy

Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium. Consider therapy modification

Regorafenib: Neomycin (Ring OUT) may decrease serum concentrations of the active metabolite(s) of Regorafenib. Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification

SORAfenib: Neomycin (Ring OUT) may decrease the serum concentration of SORAfenib. Monitor therapy

Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. Monitor therapy

Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Vitamin K Antagonists (eg, warfarin): Neomycin (Ring OUT) may enhance the anticoagulant effect of Vitamin K Antagonists. Monitor therapy

See also:
What are the possible side effects of Beclometasone (Ring OUT)?

Nasal Inhaler

In general, side effects in clinical studies have been primarily associated with the nasal mucous membranes.

Adverse reactions reported in controlled clinical trials and long-term open studies in patients treated with beclomethasone dipropionate nasal inhaler are described below.

Sensations of irritation and burning in the nose (11 per 100 patients) following the use of beclomethasone dipropionate nasal inhaler have been reported. Also, occasional sneezing attacks (10 per 100 adult patients) have occurred immediately following the use of the intranasal inhaler. This symptom may be more common in children. Rhinorrhea may occur occasionally (1 per 100 patients).

Localized infections of the nose and pharynx with Candida albicans have occurred rarely.

Transient episodes of epistaxis have been reported in 2 per 100 patients.

Rare cases of ulceration of the nasal mucosa and instances of nasal septum perforation have been spontaneously reported.

Reports of headache, light-headedness, dryness and irritation of the nose and throat, and unpleasant taste and smell have been received. There are rare reports of loss of taste and smell.

Rare instances of wheezing, cataracts, glaucoma and increased intraocular pressure have been reported following the intranasal application of aerosolized corticosteroids.

Rare cases of immediate and delayed hypersensitivity reactions, including urticaria, angioedema, rash, and bronchospasm, have been reported following the oral and intranasal inhalation of beclomethasone.

Systemic corticosteroid side effects were not reported during the controlled clinical trials. If recommended doses are exceeded, however, or if individuals are particularly sensitive, symptoms of hypercorticism (i.e., Cushing's syndrome, could occur).

Nasal Spray

In general, side effects in clinical studies have been primarily associated with irritation of the nasal mucous membranes. Rare cases of immediate and delayed hypersensitivity reactions, including urticaria, angioedema, rash, and bronchospasm, have been reported following the oral and intranasal inhalation of beclomethasone dipropionate.

Adverse reactions reported in controlled clinical trials and open studies in patients treated with beclomethasone dipropionate nasal spray are described below.

Mild nasopharyngeal irritation following the use of beclomethasone aqueous nasal spray has been reported in up to 24% of patients treated, including occasional sneezing attacks (about 4%) occurring immediately following use of the spray. In patients experiencing these symptoms, none had to discontinue treatment. The incidence of transient irritation and sneezing was approximately the same in the group of patients who received placebo in these studies, implying that these complaints may be related to vehicle components of the formulation.

Fewer than 5 per 100 patients reported headache, nausea, or lightheadedness following the use of beclomethasone dipropionate nasal spray. Fewer than 3 per 100 patients reported nasal stuffiness, nosebleeds, rhinorrhea, or tearing eyes.

Rare cases of ulceration of the nasal mucosa and instances of nasal septum perforation have been spontaneously reported.

Reports of dryness and irritation of the nose and throat, and unpleasant taste and smell have been received. There are rare reports of loss of taste and smell.

Rare instances of wheezing, cataracts, glaucoma, and increased intraocular pressure have been reported following the use of intranasal beclomethasone.

See also:
What are the possible side effects of Clotrimazole (Ring OUT)?

Applies to Clotrimazole (Ring OUT): lozenge/troche

In addition to its needed effects, some unwanted effects may be caused by Clotrimazole (Ring OUT) (the active ingredient contained in Clotrimazole (Ring OUT) Troche). In the event that any of these side effects do occur, they may require medical attention.

Minor Side Effects

Some of the side effects that can occur with Clotrimazole (Ring OUT) may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:

Note: Some of the side effects, such as abdominal or stomach cramping or pain or diarrhea, usually occur only when the medicine is swallowed

• Abdominal or stomach cramping or pain
• diarrhea
• itching
• nausea or vomiting
• unpleasant mouth sensations

See also:
What are the possible side effects of Neomycin (Ring OUT)?

Applies to Neomycin (Ring OUT): oral solution, oral tablet

In addition to its needed effects, some unwanted effects may be caused by Neomycin (Ring OUT) (the active ingredient contained in Neomycin (Ring OUT)). In the event that any of these side effects do occur, they may require medical attention.

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking Neomycin (Ring OUT):

Rare

• Any loss of hearing
• clumsiness
• diarrhea
• difficulty in breathing
• dizziness
• drowsiness
• greatly decreased frequency of urination or amount of urine
• increased amount of gas
• increased thirst
• light-colored, frothy, fatty-appearing stools
• ringing or buzzing or a feeling of fullness in the ears
• skin rash
• unsteadiness
• weakness

Minor Side Effects

Some of the side effects that can occur with Neomycin (Ring OUT) may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:

• Irritation or soreness of the mouth or rectal area
• nausea or vomiting